| In millions, except per share items | Jun-30-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues: | | | | | | | | |
| Clinical treatment programs - US | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
| Clinical treatment programs - US growth | 40.0% | 12.0% | -36.4% | 30.4% | 17.9% | 19.0% | -8.3% | -42.5% |
| Total Revenues | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
| Total Revenues growth | 40.0% | 12.0% | -36.4% | 30.4% | 17.9% | 19.0% | -8.3% | -42.5% |
| Costs and Expenses: | | | | | | | | |
| Production costs | | | | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 |
| Research and development | 3.0 | 2.1 | 1.4 | 2.5 | 1.0 | 2.9 | 2.0 | 1.3 |
| General and administrative | 2.6 | 3.5 | 5.2 | 2.2 | 2.1 | 2.6 | 1.8 | 2.1 |
| Total Costs and Expenses | 5.5 | 25.7 | 6.5 | 4.7 | 3.2 | 7.5 | 4.0 | 3.7 |
| Operating loss | -5.5 | -5.6 | -6.5 | -4.7 | -3.2 | -7.4 | -3.9 | -3.7 |
| Operating margin | -13002.4% | -9921.4% | -31052.4% | -15650.0% | -9551.5% | -14890.0% | -11906.1% | -16165.2% |
| Gain (Loss) on investments | -0.1 | 0.1 | -0.4 | -0.5 | -0.9 | -0.2 | | |
| Interest and other income | 0.3 | 0.3 | 0.2 | 0.1 | | | 0.0 | |
| |
| Interest expense and other finance costs | | | | | | | | |
| Redeemable warrants valuation adjustment | | | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 |
| Gain from sale of Income tax operating losses | 0.3 | 0.7 | 0.3 | 0.2 | 0.2 | 1.8 | 0.1 | 0.3 |
| Net Loss | -4.9 | -4.4 | -6.4 | -4.9 | -3.8 | -5.8 | -3.8 | -5.9 |
| |
| Basic loss per share | ($0.10) | ($0.09) | ($0.13) | ($0.10) | ($0.08) | ($0.12) | ($0.08) | ($0.12) |
| Diluted loss per share | ($0.10) | ($0.09) | ($0.13) | ($0.10) | ($0.08) | ($0.12) | ($0.08) | ($0.12) |
| Weighted average shares outstanding basic | 48.4 | 0.0 | 48.1 | 48.0 | 48.0 | 0.2 | 47.8 | 47.8 |
| |
| Weighted average shares outstanding diluted | 48.4 | | | 48.0 | | | | |